US › Healthcare

Vanda Pharmaceuticals Inc (VNDA)

US · Healthcare · Biotechnology

$5.33+1.91%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$51.7M
Revenue YoY
+3.4%
Net profit
$-48.6M
Profit YoY
-64.7%
EPS
$-0.46
EPS estimate
$-0.50
Net margin
-93.9%

EPS came in at -0.46 against a street estimate of -0.50 — a beat of 8.0%.

Key statistics

Market cap
$314.5M
Forward P/E
103.1
P/B
1.09
Book value
$4.67
EPS (TTM)
$-4.06
52-week high
$9.94
52-week low
$4.14
50-day MA
$5.91
200-day MA
$6.52
Beta
0.64

Analyst view

Analysts rate Vanda Pharmaceuticals Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $14.12.

Shareholding

Insiders
6.65%
Institutions
78.76%

Largest institutional holders

FundStake
BlackRock Inc12.10%
Renaissance Technologies Corp6.25%
State Street Corp5.01%
AIGH Capital Management, LLC4.57%
Vanguard Capital Management, LLC4.13%
Millennium Management LLC3.13%
Acadian Asset Management LLC2.99%
Dimensional Fund Advisors, Inc.2.95%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vanda Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.